Published in J Clin Endocrinol Metab on July 14, 2010
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study. Virchows Arch (2014) 1.99
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle (2011) 1.67
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol (2012) 1.63
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 1.39
German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg (2013) 1.23
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid (2013) 1.12
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery (2012) 0.94
Managing thyroid microcarcinomas. Yonsei Med J (2012) 0.93
BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer (2015) 0.91
Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid (2013) 0.87
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol (2016) 0.86
RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab (2013) 0.86
Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics (2011) 0.86
Cancer: Small papillary thyroid cancers--is BRAF of prognostic value? Nat Rev Endocrinol (2011) 0.85
The association between BRAF (V600E) mutation and pathological features in PTC. Eur Arch Otorhinolaryngol (2014) 0.84
Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget (2016) 0.82
VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Arch (2015) 0.81
The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch (2011) 0.81
Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croat Med J (2014) 0.81
Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch (2015) 0.80
Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy. Curr Genomics (2011) 0.80
Nodal metastases in thyroid cancer: prognostic implications and management. Future Oncol (2016) 0.80
A papillary thyroid microcarcinoma revealed by a single bone lesion with no poor prognostic factors. Case Rep Endocrinol (2013) 0.79
Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Cancer Med (2016) 0.79
Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Int J Clin Exp Pathol (2015) 0.78
BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Mod Pathol (2015) 0.78
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians. Endocrinol Metab (Seoul) (2015) 0.77
Extensive bone metastases as the initial symptom of papillary thyroid microcarcinoma: A case report. Exp Ther Med (2015) 0.77
Evaluation and management of the pediatric thyroid nodule. Oncologist (2014) 0.76
BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy. Langenbecks Arch Surg (2013) 0.76
Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma. Nucl Med Mol Imaging (2015) 0.75
Tall Cell Variant Papillary Thyroid Carcinoma in Saudi Patients: A clinicopathological and Outcomes Analysis. Saudi Med J (2016) 0.75
Thyroid function: optimizing molecular testing in thyroid nodule cytology. Nat Rev Endocrinol (2012) 0.75
Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer. Curr Genomics (2014) 0.75
The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications. Curr Genomics (2017) 0.75
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
Europe is iodine deficient. Lancet (2003) 2.99
American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract (2010) 2.97
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Clinical performance of access flap surgery in the treatment of the intrabony defect. A systematic review and meta-analysis of randomized clinical trials. J Clin Periodontol (2011) 2.75
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery (2012) 2.29
Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol (2012) 2.27
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol (2010) 1.97
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid (2014) 1.81
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab (2002) 1.81
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res (2012) 1.80
Minimally invasive video-assisted thyroidectomy: multiinstitutional experience. World J Surg (2002) 1.80
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab (2004) 1.75
Modified lateral neck lymphadenectomy: prospective randomized study comparing harmonic scalpel with clamp-and-tie technique. Otolaryngol Head Neck Surg (2009) 1.72
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery (2002) 1.71
Relative potencies and additivity of perchlorate, thiocyanate, nitrate, and iodide on the inhibition of radioactive iodide uptake by the human sodium iodide symporter. Thyroid (2004) 1.69
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab (2010) 1.68
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab (2010) 1.63
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab (2012) 1.62
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
The impact of aerators on water contamination by emerging gram-negative opportunists in at-risk hospital departments. Infect Control Hosp Epidemiol (2014) 1.52
Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab (2007) 1.51
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res (2007) 1.47
Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid (2012) 1.45
The occurrence of acute myocardial infarction in Italy: a five-year analysis of hospital discharge records. Aging Clin Exp Res (2010) 1.44
Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens (2010) 1.43
Prevalence of left ventricular hypertrophy and determinants of left ventricular mass in obese women. High Blood Press Cardiovasc Prev (2012) 1.42
Randomized controlled trial of harmonic scalpel use during thyroidectomy. Arch Otolaryngol Head Neck Surg (2006) 1.40
Exacerbation of autoimmune thyroiditis following bilateral adrenalectomy for Cushing's syndrome. Thyroid (2010) 1.39
Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism. J Hypertens (2008) 1.39
The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.36
Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab (2004) 1.32
RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab (2007) 1.31
Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid (2013) 1.27
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer (2008) 1.26
Minimally invasive video-assisted thyroidectomy for benign thyroid disease: an evidence-based review. World J Surg (2008) 1.25
Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology (2010) 1.22
Assessment of nodular goitre. Best Pract Res Clin Endocrinol Metab (2010) 1.20
Minimally invasive thyroidectomy in the treatment of well differentiated thyroid cancers: indications and limits. Curr Opin Otolaryngol Head Neck Surg (2010) 1.19
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab (2011) 1.18
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab (2005) 1.17
Artificial neural networks in the outcome prediction of adjustable gastric banding in obese women. PLoS One (2010) 1.17
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.16
Universal neonatal audiological screening: experience of the University Hospital of Pisa. Ital J Pediatr (2011) 1.15
Minimally invasive video-assisted thyroidectomy: five years of experience. J Am Coll Surg (2004) 1.15
Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J Proteome Res (2008) 1.14
Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab (2008) 1.13
Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab (2012) 1.12
Minimally invasive video-assisted thyroidectomy: an analysis of results and a revision of indications. Surg Endosc (2011) 1.10
Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol (2007) 1.09
Extent of surgery in thyroglossal duct carcinoma: reflections on a series of eighteen cases. Thyroid (2004) 1.09
Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes Cancer (2002) 1.09
Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother (2008) 1.08
Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies. J Clin Endocrinol Metab (2012) 1.08
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab (2009) 1.08